


**Add-On Treatment with Pipamperon 8-12 (mean 9) mg (bid) after Treatment with Citalopram 10-20 (mean 30) mg (bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17 Totalscore = 29 at Baseline in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials\***

**HDRS-17 REDUCTION OVER 8 WEEKS IN MDD**




A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000

**BEST AVAILABLE COPY**

Figure 1

# HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (duloxetine) in MAJOR DEPRESSION




COMBO PIPAMPERON AS ADD-ON -  
CITALOPRAM WITH PIPAMPERON 8-  
12mg/day (mean 9mg/day) 20-60  
(mean 33) days after the treatment with  
the SSRI (n=5)

DULOXETINE 40-120 mg/day (n=152)  
(Goldstein et al, J. Clin. Psychiatry (in  
press))

Figure 2

# REMISSION RATES (HDRS-17 $\leq 7$ ): COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (venlafaxine) vs SSRI's vs PLACEBO in MAJOR DEPRESSION




**COMBO PIPAMPERON AS ADD-ON - CITALOPRAM WITH PIPAMPERON 8-12mg/day (mean 9mg/day) 20-60 (mean 33) days after the treatment with the SSRI (n=5)**  
**SNRI Venlafaxine - Meta-analysis of Thase et al, Br J Psychiatry 2001; 178: 234-241**  
**SSRI's - Meta-analysis of Thase et al, Br J Psychiatry 2001; 178: 234-241**  
**PLACEBO - Meta-analysis of Thase et al, Br J Psychiatry 2001; 178: 234-241**

Figure 3

**Foregoing Treatment During 1-5 (mean 4) days with Pipamperon 8-12 (mean 10) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-50 (mean 26) mg/day (bid) (PICIT FG 1-5) in MDD (HDRS-17 at BL = 23) in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials\***

### HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



**A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000)**

Figure 4

# HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION




Figure 5

# REMISSION RATES (HDRS-17 $\leq 7$ ): COMBO PIPAMPERON-CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (venlafaxine) in MAJOR DEPRESSION





Figure 6

**Foregoing Treatment During 6-8 (mean 7) days with Pipamperon 8-12 (mean 11) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-40 (mean 30) mg/day (bid) (PICIT FG 6-8) in MDD (HDRS-17 at BL = 28 in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials\***

**HDRS-17 REDUCTION OVER 8 WEEKS IN MDD**



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000

BEST AVAILABLE COPY

Figure 7



# HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 7 DAYS WITH PIPAMPERON 11mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION





Figure 8



**Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials\***

**HDRS-17 REDUCTION OVER 8 WEEKS IN MDD**



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57, APR 2000)

BEST AVAILABLE COPY

Figure 9

# **HDRS-17 CHANGE FROM BASELINE: Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI duloxetine in MAJOR DEPRESSION**




Figure 10

# **REMISSION RATES (HDRS-17 $\leq 7$ ): Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI venlafaxine in MAJOR DEPRESSION**





Figure 11

**Y-BOCS TOTALSCORE: Foregoing & Add-On Treatment with  
Pipamperon 8-16 mg/day (bid) and Citalopram 30-80 mg/day (bid)  
in comparison with the SSRI fluvoxamine in OCD**



BEST AVAILABLE COPY

Figure 12

**Y-BOCS OBSESSION SCORE: Foregoing & Add-On Treatment  
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day  
(bid) in comparison with the SSRI fluvoxamine in OCD**





Figure 13

**Y-BOCS COMPULSION SCORE: Foregoing & Add-On Treatment  
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day  
(bid) in comparison with the SSRI fluvoxamine in OCD**




BEST AVAILABLE COPY

Figure 14

# CGI-SEVERITY SCORE: Foregoing & Add-On Treatment with Pipamperon 8 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the

## SSRI in Panic Disorder



○ Paroxetine in the treatment of panic disorder, Journal of Clinical Psychiatry 65: 405-413, No. 3, Mar 2004

✕ COMBO PIPAMPERON-CITALOPRAM (n=3)

✱ Sertraline in the treatment of panic disorder, Journal of Clinical Psychiatry 65: 405-413, No. 3, Mar 2004

BEST AVAILABLE COPY

Figure 15